{"id":5895,"date":"2025-05-21T22:18:05","date_gmt":"2025-05-21T22:18:05","guid":{"rendered":"https:\/\/medical-article.com\/?p=5895"},"modified":"2025-05-21T22:18:05","modified_gmt":"2025-05-21T22:18:05","slug":"can-most-favored-nation-mfn-be-integrated-within-the-medicare-drug-price-negotiation-program","status":"publish","type":"post","link":"https:\/\/medical-article.com\/?p=5895","title":{"rendered":"Can most favored nation (MFN) be integrated within the Medicare Drug Price Negotiation program?"},"content":{"rendered":"<p>Likely \u2018<strong>no<\/strong>\u2018.  While CMS can consider drug prices as part of IRA\u2019s Medicare Drug Price Negotiation, it is limited to considering only U.S. market data.  Here is an <a href=\"https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text\">excerpt from the IRA text<\/a>:<\/p>\n<p>For purposes of negotiating the maximum fair price  of a selected drug under this part with the manufacturer of the drug,  the Secretary shall consider the following factors, as applicable to the  drug, as the basis for determining the offers and counteroffers under subsection (b) for the drug<\/p>\n<p>\u2026<br \/>(E) Market data and revenue and sales volume data for the drug <strong>in the United States.<\/strong> <\/p>\n<p>https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text (emphasis mine)<\/p>\n<p>Thus, while in theory MFN could be integrated into the Medicare Drug Price Negotiation program, the IRA legislation restricts CMS\u2019s use of drug market data to include only market data in the U.S.  Of course, the law could be changed, but this of course complicates the implementation of MFN as part of the current Medicare Drug Price Negotiation program.  Kristi Martin from the Centers for Medicare and Medicaid Services mentioned this issue in <a href=\"https:\/\/www.healthcare-economist.com\/2025\/05\/15\/what-are-concerns-with-ira-drug-price-negotations-for-part-b-drugs\/\">her ISPOR Panel last week<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Likely \u2018no\u2018. While CMS can consider drug prices as part of IRA\u2019s Medicare Drug Price Negotiation, it is limited to considering only U.S. market data. Here is an excerpt from the IRA text: For purposes of negotiating the maximum fair price of a selected drug under this part with the manufacturer of the drug, the&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-5895","post","type-post","status-publish","format-standard","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/5895"}],"collection":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5895"}],"version-history":[{"count":0,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/5895\/revisions"}],"wp:attachment":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}